JPMorgan Chase & Co. Reiterates “Overweight” Rating for St. Jude Medical (STJ)
St. Jude Medical (NYSE:STJ)‘s stock had its “overweight” rating reiterated by stock analysts at JPMorgan Chase & Co. in a report issued on Thursday. They currently have a $81.00 target price on the stock, up from their previous target price of $74.00. JPMorgan Chase & Co.’s price objective indicates a potential upside of 19.72% from the company’s current price.
St. Jude Medical (NYSE:STJ) traded down 1.17% during mid-day trading on Thursday, hitting $66.87. 1,271,311 shares of the company’s stock traded hands. St. Jude Medical has a 52 week low of $49.94 and a 52 week high of $71.90. The stock’s 50-day moving average is $67.61 and its 200-day moving average is $65.28. The company has a market cap of $19.006 billion and a P/E ratio of 26.32.
St. Jude Medical (NYSE:STJ) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $1.02 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.00 by $0.02. The company had revenue of $1.45 billion for the quarter, compared to the consensus estimate of $1.44 billion. During the same quarter last year, the company posted $0.96 earnings per share. St. Jude Medical’s revenue was up 3.2% compared to the same quarter last year. Analysts expect that St. Jude Medical will post $3.99 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of St. Jude Medical in a research note on Thursday. They now have a $71.00 price target on the stock. Separately, analysts at Barclays reiterated an “overweight” rating on shares of St. Jude Medical in a research note on Thursday. They now have a $78.00 price target on the stock, up previously from $75.00. Finally, analysts at Citigroup Inc. reiterated a “sell” rating on shares of St. Jude Medical in a research note on Thursday. They now have a $57.00 price target on the stock, up previously from $53.00. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $69.41.
St. Jude Medical, Inc (NYSE:STJ) develops, manufactures and distributes cardiovascular medical devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.